Baifan Biotechnology (Shanghai) Co., Ltd. will establish a monoclonal antibody drug R&D and production base integrating R&D, clinical research, production, and sales in the Fengxian Lingang Intelligent Manufacturing Park. The therapeutic areas of its products cover various diseases with limited traditional treatment options, such as tumors, autoimmune diseases, and metabolic diseases, providing patients with more choices, alleviating or avoiding the suffering of radiotherapy and chemotherapy, and improving patients' quality of life. The current total investment amounts to RMB 690 million. It is expected that within three years after completion, annual sales will exceed RMB 1 billion, breaking the monopoly of imported products and reducing patients' medical burden.
Corporate Vision
Provide society with "Leading Therapeutics for Society"
Provide patients with "Attainable Quality Life for Patients"
Provide the industry with "Frontier Standard for Biopharmaceuticals"
Provide clients with "Affordable & Reliable Solution for Clients"
Baifan Biotechnology, leveraging its existing monoclonal antibody drug R&D and production platform, aims for short-term goals of developing biosimilar and innovative monoclonal antibody drugs under research, and medium- to long-term goals of building a large biopharmaceutical industry. Positioned for the domestic market and oriented towards the mainstream European and American markets, it plans to build a large biopharmaceutical company with international competitiveness within 5 to 10 years. We have multiple monoclonal antibody drug projects with strong market competitiveness, covering broad-spectrum anti-cancer, cardiovascular diseases, autoimmune diseases, and other pharmaceutical fields, including both mature biosimilars and brand-new innovative biologics. We have mastered core technologies in drug discovery, process development, and scale-up, established mature and effective platforms, and maintained a rigorous quality management system.
Our Architecture
Clinical research: cell process, purification process, formulation process, analytical development
Technology transfer and clinical research: cell pilot, purification pilot, formulation pilot
Commercial production: bulk drug substance production, formulation filling, cold chain logistics, QC, warehouse management, sales network
Our Capabilities
Monoclonal antibody drug industrialization platform:
Based on QbD concepts, we conduct DOE design, optimize processes for selected high-quality cell lines, and obtain clinical and commercial production processes that meet CFDA, FDA, and EU regulatory requirements. We ensure successful stepwise process scale-up from laboratory scale (shake flasks, 3L, 10L) to pilot scale (50L, 200L, 500L) and up to commercial production scale (2000L).
What does Baifan Biotechnology (Shanghai) Co., Ltd. require? Who is Baifan hiring? Baifan recruitment: 工厂生产类占比最多占45.9%，其次是生物/制药/化工/环保类占44.3%. What education can get in at Baifan? 本科占比最多占55.7%，其次是硕士占21.3%. High education required at Baifan? 硕士占21.3%. Work experience required at Baifan? 不限占比最多占29.5%，其次是3-5年占26.2%. Where are the job locations at Baifan? 上海占比最多占100%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
